Late clinical-stage nanomedicine company, Nanobiotix, has announced its cooperation with the University of Texas MD Anderson Cancer Center to run immunotherapeutic pre-clinical research combining NBTXR3 — the company’s lead product — with Nivolumab. more


Biotechnology company, GamaMabs Pharma, has received orphan drug designation from the US Food and Drug Administration (FDA) for its lead compound GM102 to treat advanced ovarian cancers. more


An immune-oncology focused biotechnology company, BriaCell, has provided a clinical update on its lead immunotherapy drug for advanced breast cancer. more


In this article, Frances Salisbury (partner) and Adam Gregory (associate) — European Patent Attorneys in the Life Sciences team at Mewburn Ellis — discuss innovation and IP of CAR-T therapies in more detail. more

, Opinion